LV11183B - Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof - Google Patents
Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof Download PDFInfo
- Publication number
- LV11183B LV11183B LVP-95-341A LV950341A LV11183B LV 11183 B LV11183 B LV 11183B LV 950341 A LV950341 A LV 950341A LV 11183 B LV11183 B LV 11183B
- Authority
- LV
- Latvia
- Prior art keywords
- esters
- derivative
- hydroxy
- active ingredient
- des
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0025—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0077—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9013981A FR2668945B1 (fr) | 1990-11-12 | 1990-11-12 | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11183A LV11183A (lv) | 1996-04-20 |
LV11183B true LV11183B (en) | 1996-10-20 |
Family
ID=9402062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-95-341A LV11183B (en) | 1990-11-12 | 1995-11-14 | Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US5266712A (es) |
EP (1) | EP0510167B1 (es) |
JP (1) | JP3281954B2 (es) |
KR (1) | KR100196895B1 (es) |
AT (1) | ATE126806T1 (es) |
BR (1) | BR9106012A (es) |
CA (1) | CA2073760C (es) |
DE (1) | DE69112379T2 (es) |
DK (1) | DK0510167T3 (es) |
ES (1) | ES2079172T3 (es) |
FI (1) | FI111545B (es) |
FR (1) | FR2668945B1 (es) |
GR (1) | GR3018117T3 (es) |
HU (1) | HU212780B (es) |
LV (1) | LV11183B (es) |
RU (1) | RU2126013C1 (es) |
WO (1) | WO1992008730A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776191B1 (fr) * | 1998-03-23 | 2002-05-31 | Theramex | Composition hormonale topique a effet systemique |
US6432936B1 (en) * | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
BRPI0116793B8 (pt) * | 2000-12-14 | 2021-05-25 | Johnson & Johnson | produtos de hormônio de esteróide e métodos para prepará-los |
DE10218106A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
DE10218107A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
MY143936A (en) | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
MXPA06003316A (es) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
WO2005055983A2 (en) * | 2003-12-09 | 2005-06-23 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
WO2005074942A1 (en) * | 2004-02-04 | 2005-08-18 | Retmed Pty Ltd | Slow release steroid composition |
US20060058276A1 (en) * | 2004-07-15 | 2006-03-16 | Oded Friedman | Processes for the preparation and purification of rocuronium bromide |
US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
CN101426475A (zh) | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
TW200825093A (en) * | 2006-08-03 | 2008-06-16 | Teva Pharma | Process for preparing clopidogrel bisulphate |
CN101961311B (zh) * | 2010-09-21 | 2012-11-21 | 中山大学 | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 |
MX358435B (es) * | 2012-06-18 | 2018-08-03 | Therapeuticsmd Inc | Capsula de estradiol soluble para insercion por via vaginal. |
CN112871079B (zh) * | 2021-01-27 | 2023-05-16 | 丽江映华生物药业有限公司 | 醋酸诺美孕酮微粒的制备方法及制备装置 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2096744A (en) * | 1932-10-27 | 1937-10-26 | Schering Corp | Hydrogenation products of follicle hormones and method of producing same |
US2361847A (en) * | 1937-09-04 | 1944-10-31 | Schering Corp | Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3 |
US2897216A (en) * | 1954-11-01 | 1959-07-28 | Schering Corp | Process for the preparation of steroidal dienes and intermediates obtained thereby |
US3053865A (en) * | 1958-03-19 | 1962-09-11 | Merck & Co Inc | Novel 16-alkyl and 16-alkylene steroids and processes |
US3007923A (en) * | 1959-01-22 | 1961-11-07 | Lab Francais Chimiotherapie | Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids |
DE2323812A1 (de) * | 1973-05-11 | 1974-11-28 | Jenapharm Veb | Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe |
GB1515284A (en) * | 1974-05-21 | 1978-06-21 | Gastaud J | Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series |
-
1990
- 1990-11-12 FR FR9013981A patent/FR2668945B1/fr not_active Expired - Fee Related
-
1991
- 1991-11-12 HU HU9202608A patent/HU212780B/hu unknown
- 1991-11-12 CA CA002073760A patent/CA2073760C/fr not_active Expired - Lifetime
- 1991-11-12 DK DK92900237.6T patent/DK0510167T3/da active
- 1991-11-12 AT AT92900237T patent/ATE126806T1/de not_active IP Right Cessation
- 1991-11-12 ES ES92900237T patent/ES2079172T3/es not_active Expired - Lifetime
- 1991-11-12 US US07/910,284 patent/US5266712A/en not_active Expired - Lifetime
- 1991-11-12 RU SU5052919A patent/RU2126013C1/ru active
- 1991-11-12 DE DE69112379T patent/DE69112379T2/de not_active Expired - Lifetime
- 1991-11-12 BR BR919106012A patent/BR9106012A/pt not_active Application Discontinuation
- 1991-11-12 JP JP50041592A patent/JP3281954B2/ja not_active Expired - Lifetime
- 1991-11-12 EP EP92900237A patent/EP0510167B1/fr not_active Expired - Lifetime
- 1991-11-12 WO PCT/FR1991/000888 patent/WO1992008730A1/fr active IP Right Grant
- 1991-11-12 KR KR1019920701658A patent/KR100196895B1/ko not_active IP Right Cessation
-
1992
- 1992-07-10 FI FI923188A patent/FI111545B/fi not_active IP Right Cessation
-
1995
- 1995-11-14 LV LVP-95-341A patent/LV11183B/lv unknown
- 1995-11-20 GR GR950403233T patent/GR3018117T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
US5266712A (en) | 1993-11-30 |
EP0510167A1 (fr) | 1992-10-28 |
CA2073760A1 (fr) | 1992-05-13 |
DE69112379D1 (de) | 1995-09-28 |
GR3018117T3 (en) | 1996-02-29 |
DK0510167T3 (da) | 1996-01-02 |
BR9106012A (pt) | 1993-01-05 |
FI923188A0 (fi) | 1992-07-10 |
KR100196895B1 (ko) | 1999-06-15 |
EP0510167B1 (fr) | 1995-08-23 |
ATE126806T1 (de) | 1995-09-15 |
DE69112379T2 (de) | 1996-03-28 |
CA2073760C (fr) | 2003-09-23 |
WO1992008730A1 (fr) | 1992-05-29 |
JPH05503305A (ja) | 1993-06-03 |
HU212780B (en) | 1996-11-28 |
ES2079172T3 (es) | 1996-01-01 |
FR2668945B1 (fr) | 1993-02-19 |
FI923188A (fi) | 1992-07-10 |
KR927003617A (ko) | 1992-12-18 |
FI111545B (fi) | 2003-08-15 |
HU9202608D0 (en) | 1992-10-28 |
JP3281954B2 (ja) | 2002-05-13 |
RU2126013C1 (ru) | 1999-02-10 |
LV11183A (lv) | 1996-04-20 |
HUT61319A (en) | 1992-12-28 |
FR2668945A1 (fr) | 1992-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV11183B (en) | Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof | |
EP2085075B1 (en) | Stable shaped particles of crystalline organic compounds | |
EP0674900A1 (fr) | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA | |
LU88001A1 (fr) | Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires | |
TW202344255A (zh) | 包含別孕烷醇酮(Brexanolone)、加那索醇酮(Ganaxolone)或祖拉諾醇酮(Zuranolone)的醫藥組合物及其用途 | |
EP0288336B1 (fr) | Dispositif auto-adhésif d'administration d'un principe actif par voie percutanée | |
WO2015002435A1 (ko) | 다중층상 유화물 구조의 경피약물전달시스템 | |
TWI341731B (en) | Process of lyophilization for the preparation of piroxicam: β-cyclodextrin inclusion compound | |
JPS61118315A (ja) | ステロイド−17−モノエステル含有クリ−ム剤 | |
US5760009A (en) | Spirostanyl glycosidal crystalline monohydrate | |
FR2719770A1 (fr) | Système matriciel pour administration transdermique d'ibuprofène et procédé de préparation. | |
US3764616A (en) | 21-phosphate esters of 17{60 -acyloxy-21 hydroxy steroids of the pregnane series | |
FR2510582A1 (fr) | Steroides esterifies en la position 17 et thio-esterifies en la position 21, leur procede de preparation et leur application comme medicament | |
US4780460A (en) | Glycoesters of estradiol and estriol | |
EP1121100B1 (fr) | Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine | |
WO2003013427A2 (en) | A method for preparing fluticasone derivatives | |
KR100788449B1 (ko) | 덱시부프로펜 현탁원료 및 현탁액제의 제조방법 | |
JPS63218663A (ja) | ジヒドロピリジン−ヒドロキシプロピルシクロデキストリン包接複合体 | |
EP0950050A1 (fr) | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues | |
y Sosa et al. | Non-polymeric Microspheres for the Therapeutic Use of Estrogens: An Innovative Technology | |
JPH0129199B2 (es) | ||
IL101260A (en) | Crystallization of organic substances of steroidal origin and the thus obtained compounds | |
MXPA00008314A (es) | Particulas configuradas estables de compuestos organicos cristalinos | |
JPS60116699A (ja) | ステロイド−環状(1→2)−β−D−グルカン包接化合物およびその製法 | |
BE631542A (es) |